

Claims

- 5 1. Combination preparation consisting of at least
 one active agent A from the group hyaluronic
 acid, the salts and fragments thereof, an active
 agent B from the group of local anaesthetics and
 derivatives thereof and if necessary further ad-
10 ditives for human and veterinary medical ther-
 apy, prophylaxis and/or metaphylaxis of degen-
 erative or traumatic articular diseases and ar-
 ticular function disorders and also articular
 cartilage and cartilage bone defects.
- 15 2. Combination preparation according to claim 1,
 characterised in that the active agents A and B
 are bonded to each other chemically or physi-
 cally, and in that the active agent B can be re-
 leased in a delayed manner.
- 20 3. Combination preparation according to at least
 one of the preceding claims,
 characterised in that the active agent A is con-
 tained in a concentration between 0.001 and 5%
25 by weight, preferably between 0.2 and 2% by
 weight.
- 30 4. Combination preparation according to at least
 one of the preceding claims,
 characterised in that the active agent B is con-
 tained in a concentration between 0.001 and 20%
 by weight, preferably between 0.001 and 5% by
 weight.
- 35 5. Combination preparation according to at least
 one of the preceding claims,

characterised in that agents with radical inter-
ceptor properties, in particular tocopherol de-
rivatives and/or ascorbic acid derivatives, are
contained as additive.

5

6. Combination preparation according to at least
one of the preceding claims,
characterised in that agents of the hyaline car-
tilage tissue, in particular glucosamine sul-
phate derivatives and/or chondroitin sulphate
derivatives, are contained as additive.

10

7. Combination preparation according to at least
one of the preceding claims,
characterised in that agents with a steroidal or
corticoidal effect, in particular glucocorti-
coids, are contained as additive.

15

8. Combination preparation according to at least
one of the preceding claims,
characterised in that non-steroidal antiphlogis-
tics, in particular indometacin, diclofenac or
salicylic acid derivatives, are contained as ad-
ditive.

20

9. Combination preparation according to at least
one of the preceding claims,
characterised in that analgesics, in particular
oxicams, aniline or anthranilic acid deriva-
tives, are contained as additive.

25

30

10. Combination preparation according to at least one of the preceding claims, characterised in that agents with an inhibitory effect on prostaglandin synthesis, in particular lipoxxygenase inhibitors, cyclo-oxygenase inhibitors and phospholipase A2 inhibitors, are contained as additive.
11. Combination preparation according to at least one of the preceding claims, characterised in that growth factors, in particular retinol or bone morphogenetic proteins (BMPs), are contained as additive.
12. Combination preparation according to at least one of the preceding claims, characterised in that vitamins, in particular vitamin A, C, B12 or biotin, are contained as additive.
13. Combination preparation according to at least one of the preceding claims, characterised in that antioxidants, in particular flavonoids or glutathione, are contained as additive.
14. Combination preparation according to at least one of the preceding claims, characterised in that agents with water-binding properties, in particular urea or arginine, are contained as additive.
15. Use of hyaluronic acid, the salts and fragments thereof in combination with at least one active agent from the group of local anaesthetics and

derivatives thereof for preparing a medicament for human and veterinary medical therapy, prophylaxis and/or metaphylaxis of degenerative or traumatic articular diseases and articular function disorders.

5

16. Use according to claim 15 for human and veterinary medical therapy, prophylaxis and/or metaphylaxis of articular cartilage and cartilage bone defects.

10

17. Use according to claim 15 for human and veterinary medical therapy, prophylaxis and/or metaphylaxis of meniscus and intervertebral disc diseases.

15

18. Use according to claim 15 in order to increase the proliferation of chondrocytes.

19. Use according to claim 15 in order to stabilise and/or regenerate articular structures, in particular of the articular cartilage and of the meniscus.

20

20. Use according to claim 15 in order to increase articular mobility.

25

21. Use according to claim 15 in order to inhibit inflammatory processes.

30

22. Use according to claim 15 in order to treat skin or mucous membrane changes.

35